Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6869 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 |
filingDate |
1994-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc8e3afbfcf74ffac2aeccd8e3b0eee2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39fb1d35ebd917d11adda5aa4b51e337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4235967c3b70cd9dede0f0c1226dadda |
publicationDate |
1995-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2142973-A1 |
titleOfInvention |
A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130 |
abstract |
It has been found that the ligands of the group of cytokins similar to Interleukin 6 (IL-6), that is Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) and Interleukin 11 (IL-11), induce formation of a receptor complex of which the membrane molecule gp 130 is a part. It is thus possible to formulate the hypothesis that two different surfaces of the protein (in this class of hormones), known as site 1 and site 2 bind to two different molecules: site 1 to the specific receptor and site 2 to gp 130. The invention allows the identification of these sites and the isolation of variants having, with respect to the wild hormone, a greater affinity for the specific receptor (superagonists and superantagonists) or affinity for gp 130 reduced or abolished (antagonists and superantagonists). The figure shows the construct pHen.DELTA. hIL-6 and the production of phasmidic particles that can be used to select agonists of Interleukin 6. |
priorityDate |
1993-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |